<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578461</url>
  </required_header>
  <id_info>
    <org_study_id>H-19164 REGKINE</org_study_id>
    <nct_id>NCT00578461</nct_id>
    <nct_alias>NCT00653289</nct_alias>
  </id_info>
  <brief_title>T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE</brief_title>
  <acronym>REGKINE</acronym>
  <official_title>T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are being asked to participate in this study because they have a cancer in their
      blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia). We
      suggest a treatment that might help them live longer without disease than other treatment
      plans would. This treatment is known as a stem cell transplant. We believe this may help the
      patient as it allows us to give much stronger doses of drugs and radiation to kill the
      diseased cells than we could give without the transplant. We also think that the healthy
      cells may help fight any diseased cells left after the transplant.

      Stem Cells are special &quot;mother&quot; cells that are found in the bone marrow (the spongy tissue
      inside bones), although some are also found in the bloodstream (peripheral blood). As they
      grow, they become either white blood cells which fight infection, red blood cells which carry
      oxygen and remove waste products from the organs and tissues or platelets, which enable the
      blood to clot. For the transplant to take place, we will collect these stem cells from a
      &quot;donor&quot; (a person who agrees to donate these cells) and give them to the patient. The patient
      has a type of blood cell cancer or other blood problem that is very hard to cure with
      standard treatments and they will receive a stem cell transplant (SCT). If they have a
      brother or sister that is a perfect match and agrees to donate, the stem cells will come from
      him/her. Before the transplant, two very strong drugs plus total body irradiation will be
      given to the patient (pre-conditioning). This treatment will kill most of the blood-forming
      cells in the bone marrow. We will then give the patient the healthy stem cells. Once these
      healthy stem cells are in the bloodstream they will move to the bone marrow (graft) and begin
      producing blood cells that will eventually mature into healthy red blood cells, white blood
      cells and platelets.

      Also, we will ask permission to draw blood from the patient so that we can measure the number
      of certain blood cells called T regulatory cells. T regulatory cells are special immune cells
      that can control or regulate the body's immune response. We want to determine whether T
      regulatory cells are important participants in graft versus host disease (GVHD), infection
      and relapse. In GVHD, certain cells from the donated marrow or blood (the graft) attack the
      body of the transplant patient (the host). GVHD can affect many different parts of the body.
      The skin, eyes, stomach and intestines are affected most often. GVHD can range from mild to
      life-threatening. We do not know whether T regulatory cells can modify these conditions. We
      want to measure these T regulatory cells and learn if these cells do influence these
      conditions. If we learn that T regulatory cells do affect these conditions, then it may be
      possible to modify these cells for the benefit of transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the transplant we will test the patients blood for viruses which can cause problems
      after the transplant. These viruses include Hepatitis B, (which causes liver damage),
      cytomegalovirus, (which causes lung disease) and HIV (which causes AIDS). If the patient is
      positive for the AIDS virus, they will not be able to undertake the transplant.

      The patient will be given 6 doses of chemotherapy with a drug called Ara C in high doses
      (every 12 hours) which will begin 8 days before their stem cell transplant. Then, another
      chemotherapy drug called cyclophosphamide will be given in high doses by vein for two days on
      the 7th and 6th days before their transplant. A drug called MESNA will be given with
      cyclophosphamide. MESNA is used to decrease the side effects caused by cyclophosphamide.
      Radiation treatment will be given to the entire body on each day for 4 days before the
      transplant. This will be done 2 times a day for 4 days. The chemotherapy and radiation
      treatment will last 8 days. The patient will receive extra radiation treatment if they have
      certain diseases (central nervous system (CNS) disease, testicular disease or other focal
      (localized) disease).

      The day after the radiation treatment is completed; the patient will receive the healthy stem
      cells by vein. Once in the bloodstream, these stem cells will go to the bone marrow and
      should begin to grow

      In prevention of GVHD, the patient will also receive medicine called FK506 as well as low
      dose methotrexate. The FK506 will be given intravenously (through the vein) initially
      starting 2 days before the transplant and later by mouth (when they are able to take oral
      medications). This drug will be given each day for several weeks. Four doses of low dose
      methotrexate will be given intravenously. The methotrexate will be given on the day after the
      transplant, 3, 6 and 11 days after the transplant. If the GVHD cannot be controlled with
      FK506, other medicines may need to be given. Your doctor will describe these medicines at
      that time.

      After the patient has their stem cell transplant, we would like to collect some blood at
      different time points after the transplantation in order to study how regulatory T cells work
      and grow after a stem cell transplant.

      To study how these cells are working in the system, blood samples will be taken each month
      for six months, at nine months, at one year, 2 years and 3 years following transplant.
      Approximately 6-8 teaspoons of blood will be collected each time. The total blood drawn for
      this study over three years should not exceed 1 and 3/4 cups. This amount is considered safe
      in adults. The amount of blood collected will be decreased in children and/or in patients
      where this amount of blood collection would not be appropriate. If the patient has a central
      line, the blood will be taken from it, so that extra needle sticks should not be needed. If
      the patient does not have a central line, they will need to have one placed. This will be a
      separate procedure for which the patient will sign a separate consent form. The patient will
      need to come to the clinic on the days of blood drawing and to be seen at Texas Children's
      Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Percentage of Treg Cells at 1 Year Post Transplant</measure>
    <time_frame>1 Year</time_frame>
    <description>The investigative intent is to determine the changes in numbers and function of the regulatory cell population using the best methods to measure this cell population. The frequency of T cells will be summarized at baseline and each time point of follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Leukemia</condition>
  <condition>Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, Hodgkin</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara C</intervention_name>
    <description>3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI-Total Body Irradiation</intervention_name>
    <description>Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients with acute or chronic leukemia or advanced Hodgkin or non Hodgkin lymphoma or
             myelodysplastic/myeloproliferative disease who are unlikely to be cured by standard
             chemotherapy treatments. This includes patients who have relapsed after standard
             chemotherapy treatments and patients in first remission with unfavorable prognostic
             features.

          -  Patient must have a genotype HLA identical stem cell donor.

        EXCLUSION CRITERIA:

          -  Patients with a life expectancy (less than or equal to 6 weeks) limited by disease
             other than leukemia.

          -  Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of
             significant cardiac dysfunction by echocardiogram (shortening fraction &lt;20%).

          -  Patients with severe renal disease (i.e., creatinine greater than 3 times normal for
             age).

          -  Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of
             predicted).

          -  Patients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or AST
             greater than 500 IU/L).

          -  Patients with severe personality disorder or mental illness.

          -  Patients with severe infection that in the estimation of the principal investigator
             prohibits the use of ablative chemotherapy.

          -  Patients who are documented HIV positive.

          -  Patients with a Karnofsky performance score &lt;60% or Lansky performance score &lt;50%.

        NOTE: Patients who would be excluded from treatment on this protocol strictly for
        laboratory or performance abnormalities can be included at the principal investigator's
        discretion after consultation with the members of the SCT Policy and Procedures Committee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Krance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>August 28, 2014</results_first_submitted>
  <results_first_submitted_qc>August 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2014</results_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>myeloproliferative disease</keyword>
  <keyword>myelodsyplastic disease</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, Hodgkin</keyword>
  <keyword>Lymphoma, non-Hodgkin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive stem cell transplantation conditioning, GVHD prevention and stem cell infusion.
Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation. Ara C: 3000 mg/m^2 - pts will receive via IV every 12 hours for 6 doses starting at 20:00 hours on day -8.Mesna: 45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
Cyclophosphamide: 45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours.TBI-Total Body Irradiation: Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4 to day -1. Stem cell Infusion is on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 26 patients were enrolled on the study and all of them received the conditioning treatment and the transplant.</population>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive stem cell transplantation conditioning, GVHD prevention and stem cell infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Percentage of Treg Cells at 1 Year Post Transplant</title>
        <description>The investigative intent is to determine the changes in numbers and function of the regulatory cell population using the best methods to measure this cell population. The frequency of T cells will be summarized at baseline and each time point of follow-up.</description>
        <time_frame>1 Year</time_frame>
        <population>Only 20 of the 26 patients enrolled were included in this analysis as only 20 patients have Treg values at 1 year.</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>All patients will be receiving a stem cell transplant on study. Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage of Treg Cells at 1 Year Post Transplant</title>
          <description>The investigative intent is to determine the changes in numbers and function of the regulatory cell population using the best methods to measure this cell population. The frequency of T cells will be summarized at baseline and each time point of follow-up.</description>
          <population>Only 20 of the 26 patients enrolled were included in this analysis as only 20 patients have Treg values at 1 year.</population>
          <units>percentage of total CD4+ cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.1" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive stem cell transplantation conditioning, GVHD prevention and stem cell infusion.
Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation. Ara C: 3000 mg/m^2 - pts will receive via IV every 12 hours for 6 doses starting at 20:00 hours on day -8.Mesna: 45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Cyclophosphamide: 45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours.TBI-Total Body Irradiation: Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4 to day -1. Stem cell Infusion is on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Death is not associated with CTCAE term - Multi-organ failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection. ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Catheter-related</sub_title>
                <description>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L) - Catheter-related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Vein</sub_title>
                <description>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L) - Vein</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection - Other: only clinical signs of infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>SGOT: serum glutamic oxaloacetic transaminase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation - Other: Severe coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Portal vein flow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>SGPT: serum glutamic pyruvic transaminase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>SGOT: serum glutamic oxaloacetic transaminase</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <description>GGT: gamma-Glutamyl transpeptidase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PTT</sub_title>
                <description>PTT: Partial Thromboplastin Time</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Krance, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-4661</phone>
      <email>rakrance@txch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

